<DOC>
	<DOCNO>NCT01291511</DOCNO>
	<brief_summary>The purpose study determine whether Iloperidone effective prevention relapse patient schizophrenia</brief_summary>
	<brief_title>Relapse Prevention Study Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Patients must understand capable communicate adequately study coordinator participate cognitive testing . Patients must agree cooperate test examination require protocol , willing comply fully treatment able ingest oral medication . Patients must understand nature study must sign informed consent document . Patients clear diagnosis schizophrenia accord DSMIV criterion least 1 year . Patients must need ongoing psychiatric treatment must document reason change treatment need might lead clinical improvement At screen patient Positive Negative Syndrome Scale ( PANSS ) 100 Clinical Global Impression Scale ( CGI ) 5 ( i.e . must severely ill bad ) . Patients must outpatients time screen inpatient treat schizophrenia least 1 week prior screen visit . Patients must history least 2 prior episode relapse impend relapse 2 year precede screen visit . Pregnant nursing ( lactate ) woman , woman plan conceive course study . Patients meet DSMIV criterion schizophreniform disorder ( 295.40 ) schizoaffective ( 295.70 ) . Patients active symptom primary psychiatric diagnosis ( Axis I ) prominent Axis II disorder would interfere compliance protocol . Patients diagnosis history suggestive chemical dependence , druginduced toxic psychosis precede 6 month ; diagnosis history abuse ( except nicotine caffeine ) within past 3 month , clinical presentation possibly confound use recreational drug alcohol . Patients positive urine drug screen ( screen visit ) . If opiate positive screen clearly due use pain kill medication , patient may screen medication discontinue enrol study urine drug screen negative . Note : Occasional user recreational drug cocaine , amphetamine , hallucinogen , parenteral drug may recruit . Patients dependent nicotine , caffeine , theophylline allow enter study . Patients mentally disabled ( moderate severe ) . Patients history coma 24 hr . Patients thought commit suicide within 6 month prior screen baseline suicide behavior within 2 year prior screen baseline . Patients think imminent risk harm others imminent legal difficulty . Patients form legal compulsion remain hospitalized undergo treatment assessment . Patients disability prevent complete study requirement . Patients know clinically significant ECG abnormality include PR interval &gt; 240 msec , QRS complex &gt; 110 msec , QTcF &gt; =450 msec , congenital long QT syndrome base central ECG reading result Treatment naive , first episode patient , Patients take iloperidone screening visit know hypersensitivity drug chemically related benzioxazoles . Note : Active medical condition minor wellcontrolled exclusionary affect risk patient study result . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Iloperdione</keyword>
	<keyword>Relapse Prevention</keyword>
</DOC>